Patents by Inventor Peter Michael Wovkulich
Peter Michael Wovkulich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9580411Abstract: The invention is concerned with the compounds of formula (I): and salts thereof, wherein X, Y, Z, R1, R2, R3, R3?, R4, R5 and R6 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of Formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.Type: GrantFiled: March 27, 2015Date of Patent: February 28, 2017Assignee: Hoffmann-La Roche Inc.Inventors: Christine E. Brotherton-Pleiss, Huifen Chen, Shaoqing Chen, Zhi Chen, Shawn David Erickson, Anthony Estrada, Kyungjin Kim, Hongju Li, Allen John Lovey, Joseph P. Lyssikatos, Yimin Qian, Sung-Sau So, Peter Michael Wovkulich, Lin Yi
-
Patent number: 9353096Abstract: The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Y, R1, R2 and R3 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are antagonists of the TRPA1 channel and may be useful in treating inflammatory diseases and disorders associated with that channel.Type: GrantFiled: April 10, 2015Date of Patent: May 31, 2016Assignee: Hoffmann-La Roche Inc.Inventors: Christine E. Brotherton-Pleiss, Zhi Chen, Shawn David Erickson, Kyungjin Kim, Hongju Li, Yimin Qian, Sung-Sau So, Peter Michael Wovkulich, Lin Yi
-
Patent number: 9334278Abstract: The present invention relates to the use of novel pyrrolo[2,3-b]]pyrazines wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.Type: GrantFiled: August 19, 2013Date of Patent: May 10, 2016Assignee: Hoffmann-La Roche Inc.Inventors: Johannes Cornelius Hermann, Joshua Kennedy-Smith, Matthew C. Lucas, Fernando Padilla, Ryan Craig Schoenfeld, Peter Michael Wovkulich
-
Publication number: 20150218170Abstract: The present invention relates to the use of novel pyrrolo[2,3-b]]pyrazines wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.Type: ApplicationFiled: August 19, 2013Publication date: August 6, 2015Inventors: Johannes Cornelius Hermann, Joshua Kennedy-Smith, Matthew C. Lucas, Fernando Padilla, Ryan Craig Schoenfeld, Peter Michael Wovkulich
-
Publication number: 20150218141Abstract: The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Y, R1 and R3 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are antagonists of the TRPA1 channel and may be useful in treating inflammatory diseases and disorders associated with that channel.Type: ApplicationFiled: April 16, 2015Publication date: August 6, 2015Applicant: HOFFMANN-LA ROCHE INC.Inventors: Christine E. Brotherton-Pleiss, Zhi Chen, Shawn David Erickson, Kyungjin Kim, Hongju Li, Allen John Lovey, Yimin Qian, Sung-Sau SO, Peter Michael Wovkulich, Lin Yi
-
Publication number: 20150218144Abstract: The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Y, R1, R2 and R3 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are antagonists of the TRPA1 channel and may be useful in treating inflammatory diseases and disorders associated with that channel.Type: ApplicationFiled: April 10, 2015Publication date: August 6, 2015Applicant: Hoffmann-La Roche Inc.Inventors: Christine E. Brotherton-Pleiss, Zhi Chen, Shawn David Erickson, Kyungjin Kim, Hongju Li, Yimin Qian, Sung-Sau So, Peter Michael Wovkulich, Lin Yi
-
Publication number: 20150197509Abstract: The invention is concerned with the compounds of formula (I): and salts thereof, wherein X, Y, Z, R1, R2, R3, R3?, R4, R5 and R6 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of Formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.Type: ApplicationFiled: March 27, 2015Publication date: July 16, 2015Applicants: GENENTECH, INC., HOFFMANN-LA ROCHE INC.Inventors: Christine E. BROTHERTON-PLEISS, Huifen CHEN, Shaoqing CHEN, Zhi CHEN, Shawn David ERICKSON, Anthony ESTRADA, Kyungjin KIM, Hongju LI, Allen John LOVEY, Joseph P. LYSSIKATOS, Yimin QIAN, Sung-Sau SO, Peter Michael WOVKULICH, Lin YI, I
-
Patent number: 8940741Abstract: This application discloses 6-(2-Hydroxymethyl-phenyl)-2-methyl-2H-pyridazin-3-one derivatives according to generic Formula I: wherein, variables X, R, and Y4, are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation, such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.Type: GrantFiled: March 1, 2013Date of Patent: January 27, 2015Assignee: Hoffmann-La Roche Inc.Inventors: Steven Joseph Berthel, Roland Joseph Billedeau, Christine E. Brotherton-Pleiss, Fariborz Firooznia, Stephen Deems Gabriel, Xiaochun Han, Ramona Hilgenkamp, Saul Jaime-Figueroa, Buelent Kocer, Francisco Javier Lopez-Tapia, Yan Lou, Lucja Orzechowski, Timothy D. Owens, Jenny Tan, Peter Michael Wovkulich
-
Patent number: 8658646Abstract: The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.Type: GrantFiled: August 31, 2012Date of Patent: February 25, 2014Assignee: Hoffmann-LaRoche Inc.Inventors: Shaoqing Chen, Javier de Vicente Fidalgo, Matthew Michael Hamilton, Johannes Cornelius Hermann, Joshua Kennedy-Smith, Hongju Li, Allen John Lovey, Matthew C. Lucas, Kin-Chun Thomas Luk, Stephen M. Lynch, Counde O'yang, Fernando Padilla, Ryan Craig Schoenfeld, Achyutharao Sidduri, Michael Soth, Ce Wang, Peter Michael Wovkulich, Xiaohu Zhang
-
Patent number: 8481540Abstract: This application discloses 6-(2-Hydroxymethyl-phenyl)-2-methyl-2H-pyridazin-3-one derivatives according to generic Formula I: wherein, variables X, R, and Y4, are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation, such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.Type: GrantFiled: August 11, 2011Date of Patent: July 9, 2013Assignee: Hoffmann-La Roche Inc.Inventors: Steven Joseph Berthel, Roland Joseph Billedeau, Christine E. Brotherton-Pleiss, Fariborz Firooznia, Stephen Deems Gabriel, Xiaochun Han, Ramona Hilgenkamp, Saul Jaime-Figueroa, Buelent Kocer, Francisco Javier Lopez-Tapia, Yan Lou, Lucja Orzechowski, Timothy D. Owens, Jenny Tan, Peter Michael Wovkulich
-
Publication number: 20130059834Abstract: The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.Type: ApplicationFiled: August 31, 2012Publication date: March 7, 2013Inventors: Shaoqing Chen, Javier de Vicente Fidalgo, Matthew Michael Hamilton, Johannes Cornelius Hermann, Joshua Kennedy-Smith, Hongju Li, Allen John Lovey, Matthew C. Lucas, Kin-Chun Thomas Luk, Stephen M. Lynch, Counde O'yang, Fernando Padilla, Ryan Craig Schoenfeld, Achyutharao Sidduri, Michael Soth, Ce Wang, Peter Michael Wovkulich, Xiaohu Zhang
-
Publication number: 20120184542Abstract: Compounds of formula and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositions for the treatment, control or amelioration of proliferative diseases, including cancer, Down syndrome or early onset Alzheimer's disease.Type: ApplicationFiled: January 12, 2012Publication date: July 19, 2012Inventors: Kevin Anderson, Yi Chen, Zhi Chen, Kin-Chun Luk, Pamela Loreen Rossman, Hongmao Sun, Peter Michael Wovkulich
-
Publication number: 20120040949Abstract: This application discloses 6-(2-Hydroxymethyl-phenyl)-2-methyl-2H-pyridazin-3-one derivatives according to generic Formula I: wherein, variables X, R, and Y4, are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation, such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.Type: ApplicationFiled: August 11, 2011Publication date: February 16, 2012Inventors: Steven Joseph Berthel, Roland Joseph Billedeau, Christine E. Brotherton-Pleiss, Fariborz Firooznia, Stephen Deems Gabriel, Xiaochun Han, Ramona Hilgenkamp, Saul Jaime-Figueroa, Buelent Kocer, Francisco Javier Lopez-Tapia, Yan Lou, Lucja Orzechowski, Timothy D. Owens, Jenny Tan, Peter Michael Wovkulich
-
Patent number: 8044213Abstract: The invention is directed to compounds of formula (1) and pharmaceutically acceptable salts thereof, methods for the preparation thereof, and methods of use thereof.Type: GrantFiled: December 10, 2009Date of Patent: October 25, 2011Assignee: Hoffmann-La Roche Inc.Inventors: Jianping Cai, Shaoqing Chen, Yi Chen, Xin-Jie Chu, Robert Alan Goodnow, Jr., Kang Le, Kin-Chun Luk, Steven Gregory Mischke, Peter Michael Wovkulich
-
Patent number: 8003785Abstract: The present invention provides PLK1 inhibitor compounds of formula I: useful in the treatment or control of cell proliferative disorders, particularly oncological disorders. These compounds and formulations containing such compounds may be useful in the treatment or control of solid tumors, such as, for example, breast, colon, lung and prostate tumors and other oncological diseases such as non-Hodgkin's lymphomas. Also provided are intermediate compounds useful in the synthesis of compounds of formula I.Type: GrantFiled: June 16, 2009Date of Patent: August 23, 2011Assignee: Takeda Pharmaceutical Company LimitedInventors: Jianping Cai, Shaoqing Chen, Xin-Jie Chu, Kin-Chun Luk, Steven Gregory Mischke, Hongmao Sun, Peter Michael Wovkulich
-
Publication number: 20110071147Abstract: Disclosed are novel 4-amino-thieno[3,2-c]pyridine-7-carboxylic acid amides, and their pharmaceutically acceptable salts and esters, that are selective inhibitors of KDR and/or FGFR kinases. These compounds and their pharmaceutically acceptable salts are anti-proliferative agents useful in the treatment or control of solid tumors, in particular solid cancerous tumors of the breast, colon, lung and prostate. Also disclosed are pharmaceutical compositions containing these compounds and methods of treating cancer using these compounds.Type: ApplicationFiled: November 23, 2010Publication date: March 24, 2011Inventors: Kin-Chun Luk, Lee Apostle McDermott, Pamela Loreen Rossman, Peter Michael Wovkulich, Zhuming Zhang
-
Patent number: 7851626Abstract: There is provided a compound of formula I and the pharmaceutically acceptable salts and esters thereof wherein X1, X2, R1, R2, R3, R4, R5 and R6 are herein described. The compounds exhibit activity as anticancer agents.Type: GrantFiled: November 27, 2006Date of Patent: December 14, 2010Assignee: Hoffmann-La Roche Inc.Inventors: Qingjie Ding, Bradford James Graves, Norman Kong, Jin-Jun Liu, Allen John Lovey, Giacomo Pizzolato, John Lawson Roberts, Sung-Sau So, Binh Thanh Vu, Peter Michael Wovkulich
-
Publication number: 20100160308Abstract: The invention is directed to compounds of formula (1) and pharmaceutically acceptable salts thereof, methods for the preparation thereof, and methods of use thereof.Type: ApplicationFiled: December 10, 2009Publication date: June 24, 2010Inventors: Jianping Cai, Shaoqing Chen, Yi Chen, Xin-Jie Chu, Robert Alan Goodnow, JR., Kang Le, Kin-Chun Luk, Steven Gregory Mischke, Peter Michael Wovkulich
-
Publication number: 20090318408Abstract: The present invention provides PLK1 inhibitor compounds of formula I: useful in the treatment or control of cell proliferative disorders, particularly oncological disorders. These compounds and formulations containing such compounds may be useful in the treatment or control of solid tumors, such as, for example, breast, colon, lung and prostate tumors and other oncological diseases such as non-Hodgkin's lymphomas. Also provided are intermediate compounds useful in the synthesis of compounds of formula I.Type: ApplicationFiled: June 16, 2009Publication date: December 24, 2009Inventors: Jianping Cai, Shaoqing Chen, Xin-Jie Chu, Kin-Chun Luk, Steven Gregory Mischke, Hongmao Sun, Peter Michael Wovkulich
-
Patent number: 7615634Abstract: Novel intermediate compounds are disclosed. These compounds are useful in the synthesis of 4-aminopyrimidine-5-one derivatives that inhibit cyclin-dependent kinases, in particular cyclin-dependent kinase 4 (Cdk4). The 4-aminopyrimidine-5-one derivatives and their pharmaceutically acceptable salts have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors.Type: GrantFiled: June 20, 2006Date of Patent: November 10, 2009Assignee: Hoffmann-La Roche Inc.Inventors: David Joseph Bartkovitz, Xin-Jie Chu, Qingjie Ding, Nan Jiang, Allen John Lovey, John Anthony Moliterni, John Guilfoyle Mullin, Jr., Binh Thanh Vu, Peter Michael Wovkulich